AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9917784
Drug: Subconjunctival mitomycin
RxNorm normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subconjunctival mitomycin C (0.25 ml of 0.2 mg/ml)
Trial: 8772214
Drug: Adjusted-dose oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjusted-dose oral anticoagulants (OAC) - acenocoumarol, target INR 2.0-3.0
Trial: 8772214
Drug: Fixed-dose subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose subcutaneous low molecular weight heparin (LMWH) - nadroparine, 60 aXa IU/kg once daily
Trial: 8772214
Drug: Adjusted-dose oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjusted-dose oral anticoagulants (OAC)
Trial: 8772214
Drug: Fixed-dose subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose subcutaneous low molecular weight heparin (LMWH) - nadroparine
Trial: 28880416
Drug: Standard osteoarthritis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard osteoarthritis treatment (Control)
Trial: 27690505
Drug: Daily (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily (25 mg) plus targeted (25 mg) naltrexone
Trial: 17522511
Drug: Multimodal management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal management protocol (intravenous fluid restriction, unrestricted oral intake with prokinetic agents, early ambulation, fixed regimen epidural analgesia)
Trial: 17522511
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (intravenous fluids to prevent oliguria, restricted oral intake until return of bowel motility, weaning regimen epidural analgesia)
Trial: 15199352
Drug: Pharmacologic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacologic treatment for hyperlipidemia
Trial: 15199352
Drug: Treatment for
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for hyperlipidemia
Trial: 3579683
Drug: Conventional speech
RxNorm normalized name: TRACH TUBE,SPEECH SZ 10 BLOM #313-30-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional speech therapy provided by professional speech pathologists twice weekly
Trial: 3579683
Drug: Emotionally supportive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emotionally supportive counseling therapy provided by professional speech pathologists at the same intervals
Trial: 786317
Drug: sympathomimetic drug
RxNorm normalized name: Sympathomimetics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sympathomimetic drug
Trial: 28668914
Drug: Dexmedetomidine (0.1-0.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (0.1-0.7 μg/kg per hour, titrated by patient-triggered doses of 0.25 μg/kg)
Trial: 27684818
Drug: Low-dose CT
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose CT with iterative model reconstruction (IMR)
Trial: 27684818
Drug: Low-dose CT
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose CT with hybrid iterative reconstruction (HIR)
Trial: 27684818
Drug: Low-dose CT
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose CT with filtered back projection (FBP)
Trial: 27684818
Drug: Routine-dose CT
RxNorm normalized name: brompheniramine tannate Chewable Tablet [BroveX CT]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine-dose CT with filtered back projection (FBP)
Trial: 24439687
Drug: Psychosomatic day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychosomatic day hospital treatment
Trial: 19197129
Drug: Remifentanil and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil and propofol administered by TCI (blood concentration: 3-5 microg/L for remifentanil and 3-5 mg/L for propofol)
Trial: 19197129
Drug: Fentanyl and
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl and propofol administered by TCI (fentanyl infusion: 2-3 microg/(kg.h), same propofol concentration as Group R)
Trial: 17496586
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of completely autologous platelet gel
Trial: 11913682
Drug: Postoperative application
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative application of estriol ointment (n = 14)
Trial: 11913682
Drug: Postoperative application
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative application of dexpanthenol ointment (n = 12)
Trial: 7796767
Drug: Purified Vi
RxNorm normalized name: VIS-410
DrugBank: VIS-410 (DB19067)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Purified Vi polysaccharide vaccine (Typhim Vi), single intramuscular injection.
Trial: 3038428
Drug: Captopril 25
RxNorm normalized name: captopril 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril 25 mg tid
Trial: 2893080
Drug: Frusemide 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frusemide 40 mg daily
Trial: 21249382
Drug: Highly fit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Highly fit adolescent football players (peak VO(2) 43.5 ± 3.4 ml kg(‐1) min(‐1))
Trial: 21249382
Drug: Untrained girls
RxNorm normalized name: minoxidil
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Untrained girls (peak VO(2) 36.0 ± 5.1 ml kg(‐1) min(‐1))
Trial: 19963157
Drug: 20 mL
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mL apple cider vinegar, 40 mL water
Trial: 19963157
Drug: 60 mL
RxNorm normalized name: Disposable Nurser 60 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mL water (placebo)
Trial: 14551525
Drug: Early statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early statin therapy
Trial: 12215193
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no early statin therapy)
Trial: 8570063
Drug: Cefotiam (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotiam (single dose)
Trial: 2773842
Drug: Intramuscular or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular or oral administration of iron
Trial: 790551
Drug: Ketoprofen 100
RxNorm normalized name: ketoprofen 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoprofen 100 mg daily
Trial: 790551
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid 3 g daily
Trial: 30520201
Drug: 1 hour
RxNorm normalized name: Product containing precisely estradiol 312.5 nanogram/1 hour prolonged-release vaginal ring (clinical drug)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 hour ≥ 155 mg/dL
Trial: 22929469
Drug: Medical management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical management consisting of intravenous fluids, prophylactic antibiotics, blood transfusions, anti-diarrheals, analgesics, and nutrition
Trial: 20334973
Drug: High-Risk Experimental
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-Risk Experimental (monthly urine screens, compliance checklists, individual and group motivational counseling)
Trial: 16320858
Drug: 0.625 mg
RxNorm normalized name: estrone 0.625 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.625 mg conjugated equine estrogen (CEE) daily and twice daily 20 mg transdermal progesterone cream (PC)
Trial: 16320858
Drug: 0.625 mg
RxNorm normalized name: estrone 0.625 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.625 mg conjugated equine estrogen (CEE) daily and 2.5 mg medroxyprogesterone acetate (MPA)
Trial: 12193430
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) treatment at 6.0 IU/m2/day for at least two years
Trial: 2698571
Drug: Gallopamil retard
RxNorm normalized name: gallopamil
DrugBank: Gallopamil (DB12923)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gallopamil retard at a dosage of 75 mg b.i.d.
Trial: 62991
Drug: No tablets
RxNorm normalized name: caffeine Oral Tablet [No Doz]
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No tablets at all
Trial: 21559803
Drug: Alcohol (n=37;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (n=37; average peak BAC=0.087 g/100 ml)
Trial: 16374471
Drug: Topical methyl
RxNorm normalized name: methylal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical methyl 5-aminolevulinate (MAL) cream at concentrations of 16-160 mg/g applied for 3 hours and 18 hours.
Trial: 16374471
Drug: Topical methyl
RxNorm normalized name: methylal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical methyl 5-aminolevulinate (MAL) cream at concentrations of 16-160 mg/g applied for 18 hours.
Trial: 8721273
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg itraconazole a day orally for 4 days
Trial: 8134169
Drug: Formula containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formula containing 0.13 mumol/L (10 micrograms/L) Se
Trial: 8134169
Drug: Formula containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formula containing 0.26‐0.33 mumol/L (20‐25 micrograms/L) Se (suggested)
Trial: 2891518
Drug: LH-RH nasal
RxNorm normalized name: LH
DrugBank: Luteinizing hormone (DB14741)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LH-RH nasal spray
Trial: 2891518
Drug: LH-RH nasal
RxNorm normalized name: LH
DrugBank: Luteinizing hormone (DB14741)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LH-RH nasal spray (including subsequent open study and second course)
Trial: 7259838
Drug: All treatment
RxNorm normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All treatment options
Trial: 12190760
Drug: Single intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intravenous cannula used for both intra‐operative and postoperative purposes
Trial: 7850328
Drug: Neoadjuvant or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant or concurrent single-agent cisplatin followed by local definitive treatment
Trial: 7850328
Drug: Chemotherapy (cisplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (cisplatin and doxorubicin)
Trial: 2182103
Drug: Spectacles treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spectacles treatment
Trial: 2182103
Drug: Spectacles treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spectacles treatment (subgroup of consistent wearers)
Trial: 2182103
Drug: Spectacles treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spectacles treatment (subgroup of inconsistent wearers)
Trial: 21310088
Drug: PURIAM110 dietary
RxNorm normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PURIAM110 dietary supplement
Trial: 11506108
Drug: Hydration with
RxNorm normalized name: Gold Bond Healing Hydration with Aloe Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydration with 15 ml/kg crystalloid immediately before spinal anesthesia
Trial: 11506108
Drug: Hydration with
RxNorm normalized name: Gold Bond Healing Hydration with Aloe Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydration with 15 ml/kg crystalloid starting with the spinal anesthetic injection
Trial: 3066854
Drug: Misonidazole (total
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Misonidazole (total dose of about 11 g/m2)
Trial: 29996798
Drug: 5% duty
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% duty cycle (DC) subthreshold laser treatment
Trial: 29996798
Drug: 15% duty
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15% duty cycle (DC) subthreshold laser treatment
Trial: 29996798
Drug: Continuous wave
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous wave (CW) laser treatment
Trial: 25190615
Drug: Intravenous potassium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous potassium replacement (IVPR)
Trial: 17965109
Drug: Intravitreal triamcinolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal triamcinolone acetonide (4 mg/0.1 ml)
Trial: 17965109
Drug: Bevacizumab (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab (1.5 mg/0.06 ml)
Trial: 12942187
Drug: Topical 17α-estradiol
RxNorm normalized name: 17β-estradiol
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical 17α-estradiol
Trial: 12942187
Drug: Topical immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical immunotherapy for alopecia areata
Trial: 12942187
Drug: Modern broad
RxNorm normalized name: broad leaved paperbark pollen extract
DrugBank: Melaleuca quinquenervia pollen (DB10478)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modern broad spectrum antimycotic agents for infectious scarring alopecias
Trial: 11190013
Drug: ketorolac 0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ketorolac 0.5% ophthalmic solution
Trial: 9001827
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate nasal spray 200 micrograms once daily (n = 77)
Trial: 9001827
Drug: Oral fluticasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral fluticasone propionate 5 mg once daily (n = 73)
Trial: 9001827
Drug: Oral fluticasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral fluticasone propionate 10 mg once daily (n = 77)
Trial: 31577081
Drug: i.v. combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. combination of ampicillin + sulbactam with daily cleaning of tonsillar lesions
Trial: 31577081
Drug: i.v. combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. combination of ampicillin + sulbactam
Trial: 29030111
Drug: LFMS treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LFMS treatment (20 min/day for 4 days)
Trial: 29030111
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment (20 min/day for 4 days)
Trial: 29030111
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment (20 min/day for 2 days followed by LFMS treatment 20 min/day for 2 days)
Trial: 2510191
Drug: L-Carnitina (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-Carnitina (1 g endovenous, per orally administered vials, tablets)
Trial: 31897572
Drug: Treatment (alcohol,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment (alcohol, hypnotics, sleep deprivation)
Trial: 31897572
Drug: Treatment-induced changes
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-induced changes in SDLP
Trial: 29984800
Drug: Loading of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loading of the tympanic membrane with 340 mg (25 λ)
Trial: 29984800
Drug: Loading of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loading of the tympanic membrane with 544 mg (40 λ)
Trial: 23623861
Drug: Standard administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard administration procedures without robot
Trial: 20850390
Drug: Intradiscal injection
RxNorm normalized name: Valrubicin Intravesical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradiscal injection of normal saline
Trial: 20850390
Drug: Intradiscal injection
RxNorm normalized name: Valrubicin Intravesical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradiscal injection of diprospan
Trial: 20850390
Drug: Intradiscal injection
RxNorm normalized name: Valrubicin Intravesical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradiscal injection of diprospan+songmeile
Trial: 19225122
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no supplements or own supplements)
Trial: 16472562
Drug: Continuous oral
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous oral contraceptive (OC) use
Trial: 16472562
Drug: Conventional oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional oral contraceptive (OC) use
Trial: 16472562
Drug: Post-OC discontinuation
RxNorm normalized name: OC 8 Adult Acne
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-OC discontinuation
Trial: 10920614
Drug: Mycobacterium w
RxNorm normalized name: Mycobacterium W Vaccine
DrugBank: Mycobacterium w. Vaccine (DB15798)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mycobacterium w antileprosy vaccine
Trial: 8847984
Drug: Magnetic fields
RxNorm normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnetic fields (ELF‐MF) therapy, 20 procedures using Aplhatron 4100 device
Trial: 8847984
Drug: Simulated treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simulated treatment (control group of 29 sawyers)
Trial: 1575065
Drug: Chlorpheniramine, 8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorpheniramine, 8 mg twice daily
Trial: 1575065
Drug: Chlorpheniramine, 12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorpheniramine, 12 mg twice daily
Trial: 1575065
Drug: Terfenadine, 120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terfenadine, 120 mg twice daily
Trial: 1575065
Drug: Astemizole, 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Astemizole, 10 mg/d
Trial: 26885791
Drug: Common antiaging
RxNorm normalized name: Common carp
DrugBank: Common carp (DB10614)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Common antiaging topical treatments (prescription tretinoin, idebenone, kinetin, polyhydroxy, lactic and glycolic acids)
Trial: 10623364
Drug: H2‐receptor antagonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H2‐receptor antagonist maintenance therapy with ranitidine (150 mg daily)
Trial: 10623364
Drug: H. pylori
RxNorm normalized name: H. PYLORI AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H. pylori eradication therapy using an omeprazole/amoxicillin/metronidazole regimen
Trial: 7582388
Drug: Azithromycin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (500 mg on day 1 and 250 mg on days 2-5)
Trial: 6893819
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg pirenzepine
Trial: 6893819
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg pirenzepine
Trial: 7267679
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg atropine
Trial: 18788415
Drug: Angiotensin‐converting enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers
Trial: 10672842
Drug: Metoprolol 100
RxNorm normalized name: metoprolol 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol 100 mg given 2 hours before ERCP
Trial: 1603291
Drug: Oxiracetam 800
RxNorm normalized name: oxiracetam 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxiracetam 800 mg b.i.d. for 90 days
Trial: 1603291
Drug: Oxiracetam 800
RxNorm normalized name: oxiracetam 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxiracetam 800 mg b.i.d. for 1 year (open follow-up)
Trial: 1603291
Drug: Oxiracetam 800
RxNorm normalized name: oxiracetam 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxiracetam 800 mg b.i.d. during late follow-up
Trial: 29382675
Drug: Internet-delivered computerised
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-delivered computerised cognitive-behavioural therapy (ICBT) as an adjunct to usual care (UC)
Trial: 25893719
Drug: 568 ml
RxNorm normalized name: petrolatum 568 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 568 ml (1 pint) water preload
Trial: 22734676
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment or usual care (Control)
Trial: 22883445
Drug: Magnesium sulfate,
RxNorm normalized name: MAGNESIUM SULFATE,ANHYDROUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium sulfate, 100 mg epidurally before anesthesia induction and 500 mg added to the infusion postoperatively
Trial: 22883445
Drug: Normal saline,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline, 5 mL epidurally before anesthesia induction
Trial: 20567177
Drug: Oral misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral misoprostol every 4 hours, up to four doses
Trial: 20567177
Drug: Oral misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral misoprostol with isosorbide mononitrate every 6 hours, up to two doses
Trial: 20567177
Drug: Oral misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral misoprostol with isosorbide mononitrate